AveXis Reports Positive Data for SMA Gene Therapy | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 17 March, 2017 by The TZ Newswire Staff

AveXis Reports Positive Data for SMA Gene Therapy

AveXis’ spinal muscular atrophy drug, AVXS-101, reported encouraging results from a Phase 1 trial.

See also
- Next Article Intel Bought Mobileye for $15.3 Billion. OurCrowd Believes Three of their CarTech Companies May be Next for Big Success
- Previous Article $TXN Maxed Out To The Upside, See The Proof
Editorial Calender

March 2017

M T W T F S S

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

« Feb Apr »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar